Non-alcoholic steatohepatitis

June 8, 2017

Oral Therapy, VK2809, Shows Potential in Treating NASH-related Fibrosis in Early Study

News, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis

The investigative therapy VK2809 showed promising results in an animal study of non-alcoholic steatohepatitis (NASH), a type of non-alcoholic fatty liver disease, Viking Therapeutics, its developer, announced. The treatment’s safety and efficacy is ... Read more

May 18, 2017May 18, 2017

Albireo Wins 2 U.S. Patents for A4250 Therapy to Treat NASH, Other Liver Diseases

Cholestasis, News, Non-alcoholic steatohepatitis

Albireo Pharma has secured two new patents from the U.S. Patent and Trademark Office (USPTO) for its lead drug candidate A4250 to treat liver diseases such as nonalcoholic steatohepatitis (NASH). Boston-based Albireo has reported promising preclinical ... Read more

May 17, 2017May 17, 2017

Monkey Studies Prove Safety, Tolerability of IVA337 Experimental Therapy for Non-alcoholic Steatohepatitis

News, Non-alcoholic steatohepatitis

Inventiva’s drug candidate IVA337, currently in Phase 2 studies for both non-alcoholic steatohepatitis (NASH) and systemic sclerosis (SSc), has shown a good safety profile in monkeys, according to a 12-month non-human primate toxicology ... Read more

May 15, 2017

Early Study to Test Bioelectronic Treatment for NASH Inflammation

News, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis

A pre-clinical study to evaluate the therapeutic potential of a bioelectronic platform in preventing and reducing inflammation in non-alcoholic steatohepatitis (NASH) is beginning, its developer, Endonovo Therapeutics, announced. This is the first of multiple ... Read more

May 10, 2017May 10, 2017

Novartis Exercises Option to Develop and Market Conatus’ Emricasan to Treat NASH

Liver cirrhosis, News, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis

Novartis is exercising an option to become the exclusive developer and global marketer of Conatus Pharmaceuticals‘ liver-disease treatment emricasan. Under the agreement, signed in December 2016, Novartis will obtain the license ... Read more

May 9, 2017

First Patient Enrolled in Phase 2 Clinical Trial of Elafibranor for Bile Duct Disease

News, Non-alcoholic steatohepatitis

GENFIT has enrolled the first patient in a Phase 2a clinical trial of elafibranor as a treatment for a liver bile duct disease known as primary biliary cholangitis (PBC). The study is recruiting ... Read more

May 8, 2017

New ‘Liver Line’ Online Community to Share Updates on Health, Research, Treatments

Alcoholic liver disease, Hepatitis, Liver cancer, Liver cirrhosis, News, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis

A new online community, called Liver Line and sponsored by Galectin Therapeutics, offers the latest information on liver health and research into liver diseases. On Liver Line, patients and the community can learn ... Read more

May 5, 2017May 5, 2017

Can-Fite’s Namodenoson to Enter NAFLD/NASH Phase 2 Clinical Trial

Liver cancer, News, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis

Can-Fite BioPharma has concluded preparations for its Phase 2 trial evaluating namodenoson (CF102) for the treatment of non-alcoholic fatty liver disease (NAFLD). The study will be conducted in two leading medical ... Read more

May 2, 2017May 12, 2017

New Study Is Examining How Doctors Manage Patients with Liver Disease

News, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis

A large observational study is looking at how doctors manage people with nonalcoholic steatohepatitis (NASH) or nonalcoholic fatty liver disease (NAFL). TARGET PharmaSolutions is conducting the study in collaboration with the biopharmaceutical company Allergan. ... Read more

April 21, 2017May 12, 2017

‘Good Cholesterol’ Therapy CER-209 Enters Phase 1 Trial for NAFLD and NASH

News, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis

Cerenis Therapeutics has initiated a Phase 1 clinical trial of CER-209 for the treatment of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). The drug is a compound that ... Read more